Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

Adrenergic Agonists: Direct-Acting Agents

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

Adrenergic Agonists: Therapeutic Classification

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predictors of Supplemental Opioid Use After Third Molar Extraction.

medRxiv : the preprint server for health sciences·2025

Same author

Chondroid Diffuse Tenosynovial Giant Cell Tumor of the Temporomandibular Joint: A Case of a Rare Maxillofacial Tumor With Unique Pathophysiology and Therapeutic Considerations.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons·2025

Same author

Correction: Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma.

Hypertension research : official journal of the Japanese Society of Hypertension·2025

Same author

Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma.

Hypertension research : official journal of the Japanese Society of Hypertension·2025

Same author

Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in adolescents, adults, and older adults: A report from the American Dental Association Science and Research Institute, the University of Pittsburgh, and the University of Pennsylvania.

Journal of the American Dental Association (1939)·2024

Same author

Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in children: A report from the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania.

Journal of the American Dental Association (1939)·2023

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

Beta-adrenergic blocking agents and dental vasoconstrictors.

Elliot V Hersh¹, Helen Giannakopoulos

¹Department of Oral Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104-6030, USA. evhersh@pobox.upenn.edu

Dental Clinics of North America

|September 14, 2010

Summary

A serious drug interaction can occur between epinephrine and nonselective beta-blockers, potentially causing high blood pressure and slow heart rate. This risk increases with higher epinephrine doses and in patients with cardiovascular disease.

Related Experiment Videos

Last Updated: Jun 8, 2026

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

Area of Science:

Cardiology
Pharmacology
Dentistry

Background:

Nonselective beta-adrenergic blocking agents can interact with vasoconstrictors like epinephrine and levonordefrin.
This interaction, though rare in dental settings, can cause significant hypertension and reflex bradycardia.

Purpose of the Study:

To review the potential clinical significance of interactions between epinephrine/levonordefrin and nonselective beta-blockers in dentistry.
To assess the dose-dependency and patient-specific factors influencing this interaction.

Main Methods:

Review of epinephrine infusion studies.
Analysis of case reports detailing adverse events.
Consideration of injection techniques and local anesthetic formulations.

Main Results:

The severity of the pressor response is dose-related, with higher epinephrine doses causing a more pronounced effect.
Intraoral submucosal injections generally result in a smaller magnitude of interaction compared to systemic administration.
Inadvertent intravascular injections and high vasoconstrictor doses exacerbate the interaction.
Patients with cardiovascular disease are particularly vulnerable.

Conclusions:

The combination of epinephrine or levonordefrin with nonselective beta-blockers presents a potentially serious risk in dental practice.
Awareness of dose-dependency, injection technique, and patient cardiovascular status is crucial for risk mitigation.